{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-22-013773","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.498570+00:00","generated_at":"2026-06-24T02:40:27.788975+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Precigen Q2 loss from cont. ops $26.1M; divests Trans Ova Genetics for $170M","bullets":["Loss from continuing ops $26.1M ($0.13 loss per share) vs $30.9M loss in Q2 2021.","Total revenues down 24% YoY; SG&A decreased 15%.","Agreed to sell Trans Ova Genetics to URUS for $170M cash upfront plus up to $10M earn-out; close expected Q3 2022.","Cash and investments $132.8M as of June 30, 2022; proceeds intended to pay convertible notes due July 2023.","Believes cash plus cost reductions provide runway into Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-22-013773","json":"https://secwatch.observer/filing/0000950103-22-013773.json","markdown":"https://secwatch.observer/filing/0000950103-22-013773.md","text":"https://secwatch.observer/filing/0000950103-22-013773.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322013773/0000950103-22-013773-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322013773/dp178450_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:40:27.788975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}